<DOC>
	<DOCNO>NCT00977080</DOCNO>
	<brief_summary>Evaluates effectiveness on-label Paricalcitol versus Cinacalcet Low-Dose Vitamin D .</brief_summary>
	<brief_title>Evaluation Effectiveness Paricalcitol Versus Cinacalcet With Low-Dose Vitamin D</brief_title>
	<detailed_description>During 4-week washout period , participant stop take cinacalcet vitamin D receptor activator ( VDRAs ) . ( Participants naive cinacalcet VDRAs wash ) . At randomization , participant enter 28-week open-label treatment period , receive either cinacalcet paricalcitol . Participants assign receive paricalcitol dose accord approve label respective geographic region ( i.e. , IV sit US Russia oral site Europe ) . Supplemental cinacalcet administer participant paricalcitol arm develop hypercalcemia ( define &gt; = 10.5 mg/dL ) . The evaluation period Weeks 21 28 .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Hyperparathyroidism , Secondary</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Alfacalcidol</mesh_term>
	<mesh_term>Cinacalcet Hydrochloride</mesh_term>
	<criteria>Inclusion Criteria 1 . Male female patient &gt; = 18 year old . 2 . Patient diagnose Stage 5 chronic kidney disease ( CKD ) receive intravenous ( IV ) oral vitamin D receptor activator ( VDRAs ) cinacalcet 8 week prior screen period naïve patient receive VDRA cinacalcet within 8 week screen . 3 . Patient maintenance HD ( hemodialysis ) 3 time weekly ( TIW ) least 3 month prior screen expect remain HD duration study . 4 . For entry PreTreatment Washout Period ( patient naïve VDRAs cinacalcet ) , patient screen laboratory value : iPTH level 130 700 pg/mL Serum Total Alkaline Phosphatase level &gt; = 40 U/L Calcium level &lt; = 10.0 mg/dL ( 2.49 mmol/L ) Calciumphosphorus product ( CaxP ) &lt; = 75 mg2/dL2 ( US ) &lt; = 70 mg2/dL2 ( nonUS ) Exclusion Criteria 1 . Patient history parathyroidectomy . 2 . Patient current malignancy ( exception basal squamous cell carcinoma skin ) , clinically significant liver disease , opinion investigator . 3 . Use known inhibitor ( i.e. , ketoconazole ) inducer ( i.e. , carbamazepine ) cytochrome P450 ( include grapefruit and/or grapefruit juice ) 3A ( CYP3A ) drug metabolize cytochrome P450 2D6 ( CYP2D6 ) ( e.g. , flecainide , vinblastine , thioridazine , tricyclic antidepressant ) within 2 week prior study drug administration . Commonly use beta blocker metoprolol carvedilol allow metabolized CYP2D6 ; thus , adjustment low dose may require . 4 . Patient known human immunodeficiency ( HIV ) positive .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Zemplar</keyword>
	<keyword>paricalcitol</keyword>
	<keyword>IMPACT SHPT</keyword>
	<keyword>Hemodialysis</keyword>
	<keyword>Chronic Kidney Disease Stage 5</keyword>
</DOC>